Hjc015233

To evaluate the effects of HD5_1–9, hBD2, STAT3-inhibitor HJC015233, and Myd88-inhibitor TJ-M2010-5 on organoid cell viability, a MTT reduction assay was performed, as previously reported [86 (link)]. Concentrations of STAT5 inhibitor STAT5-IN-1 and p38 inhibitor SB203 580 were already identified in previous work [86 (link)]. Organoids were incubated with HD5_1–9 (3.6, 36, 360 ng/µL, solved in BSA/PBSO), or hBD2 (3.6, 36, 360 ng/µL, solved in BSA/PBSO), or HJC015233 (0.5, 5, 50 µg, solved in DMSO; Selleckchem, Houston, TX, USA), or TJ-M2010-5 (100, 50, 5 µM solved in DMSO; MedChemExpress, Sollentuna, Sweden), or with a corresponding amount of BSA/PBSO or DMSO as control for 30 h.

Organoids were treated with HD5_1–9 (1.17 µM, solved in BSA/PBSO), or hBD2 (0.027 µM, solved in BSA/PBSO), or corresponding amount of BSA/PBSO as control for 30 h. Furthermore, cells were incubated with HD5_1–9 or hBD2 and STAT3-inhibitor HJC015233 (5 µg, solved in DMSO; Selleckchem, Houston, TX, USA), or STAT5-inhibitor STAT5-IN-1 (5 µM, solved in DMSO; Selleckchem, Planegg, Germany), or p38 inhibitor SB203 580 (5.303 mM, solved in DMSO; Sigma-Aldrich, Darmstadt, Germany), or Myd88 inhibitor TJ-M2010-5 (100 µM, solved in DMSO; MedChemExpress, Sollentuna, Sweden) for 30 h. A corresponding amount of DMSO was used as a control.